Bone metastases in prostate cancer (PCa) have important prognostic significance, and
imaging modalities used for PCa staging should have high sensitivity for detecting such …

Aim The purpose of this study was to investigate the diagnostic performance of 68 Ga-PSMA-
11 PET/CT in the evaluation of bone metastases in metastatic prostate cancer (PC) patients …

While Tc-99m MDP bone scan (BS) remains the conventional standard for detection of bone
metastasis in prostate cancer, newly FDA-approved imaging with PSMA-based 18 F …

The purpose of this study was to compare the diagnostic performance of 18F-DCFBC
PET/CT, a first-generation 18F-labeled prostate-specific membrane antigen (PSMA) …

The aim of this study was to compare the diagnostic tools-18 F-PSMA-1007 positron
emission tomography (PET/CT), magnetic resonance imaging (MRI) and bone scintigraphy …

Background 68Ga‐labelled prostate‐specific membrane antigen (PSMA) is a promising PET
ligand for the detection of prostate cancer. Little attention has been given to the ability of …

Purpose Current standard of care conventional imaging modalities (CIM) such as X-ray
computed tomography (CT) and bone scan can be limited for detection of metastatic prostate …

Purpose Prostate-Specific Membrane Antigen (PSMA) PET/CT has been introduced as a
sensitive method for characterizing metastatic prostate cancer. The purpose of this study is …

Prostate cancer (PCa) is the most common noncutaneous malignancy in men. 1 Although a
large proportion of patients diagnosed with PCa will be cured by definitive local therapy (ie …

Bone is the most common site of distant metastatic spread in prostate adenocarcinoma.
Prostate-specific membrane antigen (PSMA) uptake has been described in both benign and …